CircRNA-ST6GALNAC6 increases the sensitivity of bladder cancer cells to erastin-induced ferroptosis by regulating the HSPB1/P38 axis

The authors describe a regulatory mechanism for ferroptosis sensitivity that is dependent on circST6GALNAC6 expression levels in bladder cancer. CircST6GALNAC6 inhibits HSPB1 and promotes cell ferroptosis by blocking the phosphorylation site (Ser-15) of HSBP1 and activating the P38 MAPK signaling pathway. Enhancing the expression of circST6GALNAC6 to promote ferroptosis, or using circST6GALNAC6 as a biomarker of ferroptosis sensitivity, is significant for the development and application of ferroptosis intervention methods. Previous studies have demonstrated that circST6GALNAC6 is a tumor suppressor in bladder cancer. However, the role of circST6GALNAC6 in ferroptosis remains unclear. In the current study, ferroptosis was induced in bladder cancer cells by erastin. Functional experiments showed that overexpression of circST6GALNAC6 promoted ferroptosis of bladder cancer cells in vitro and in vivo. Mechanistic studies revealed that circST6GALNAC6 bound to the N-terminus of small heat shock protein 1 (HSPB1) and thus blocked the erastin-induced phosphorylation of HSPB1 at the Ser-15 site, a phosphorylation site in the protective response to ferroptosis stress. In addition, protein kinase C inhibited circST6GALNAC6-induced ferroptosis by increasing the overall phosphorylation level of HSPB1, further demonstrating the role of phosphorylation activation of HSPB1 in resistance to ferroptosis. Finally, the involvement of the HSPB1/p38 MAPK pathway in the downstream signal transduction of circST6GALNAC6 in bladder cancer ferroptosis regulation was determined. The regulatory mechanism of ferroptosis sensitivity dependent on circST6GALNAC6 expression levels in bladder cancer was revealed as circRNA regulation of various protein functions. CircST6GALNAC6 inhibits HSPB1 and promotes cell ferroptosis by occupying the phosphorylation site (Ser-15) of HSBP1 and activating the P38 MAPK signaling pathway. Therefore, enhancing the expression of circST6GALNAC6 to promote ferroptosis or using circST6GALNAC6 as a biomarker of ferroptosis sensitivity is of considerable importance to the development and application of ferroptosis intervention methods in bladder cancer.

Automated summary

This study describes a regulatory mechanism for ferroptosis sensitivity in bladder cancer that is dependent on the expression levels of circST6GALNAC6. CircST6GALNAC6 inhibits HSPB1 and promotes cell ferroptosis by blocking the phosphorylation site of HSPB1 and activating the P38 MAPK signaling pathway. Enhancing the expression of circST6GALNAC6 or using it as a biomarker for ferroptosis sensitivity is significant for the development and application of ferroptosis intervention methods in bladder cancer.